Visit StopPain.org Visit HealthandHealingNY.org
Back to Home    
Visit Our ProgramsIntroduction to Chronic PainLow Back PainPost-Herpetic Neuralgia
  Introduction  
  Frequency of Occurence  
  Predisposing Factors  
  Symptoms  
  Causes  
  Diagnosis  
  Integrative Pain Therapy
   Conventional
   Complementary
 
  Recommendations  
  References  

 

Print This Page

Conventional Approaches

Pharmacological Management

The selection of a drug or drugs for PHN is largely a trial-and-error process, which is influenced by the availability of some studies of specific drugs and by the medical assessment of the patient. The most commonly used treatments are as follows:

  • Anesthetic skin patches: Some patients with PHN benefit from using local anesthetics because they reduce the pain messages that the damaged nerves send to the brain. Topical lidocaine patches were approved by the United States Food and Drug Administration in 1999 for PHN. The patches are applied to the painful area for at least 12 hours per day. Studies show that a majority of patients treated with the patch reported moderate or greater pain relief (Kanazi, 2000, Rowbotham, 1995 and 1996). Topical lidocaine in either gel or patch form can relieve allodynia in patients with PHN. In another recent study, the topical lidocaine patch provided significantly more pain relief for PHN than a placebo patch, did not cause systemic side effects, and was simple to use (Galer, 1999).

  • Topical capsaicin cream: Capsaicin, a chemical found in chili peppers, is a main ingredient in certain pain relieving creams currently available for the treatment of a number of pain conditions Regular and cumulative topical applications of capsaicin cream have been shown to produce pain relieving effects in some painful medical conditions, including PHN (Long, 2001). In one double-blind clinical trial, cream containing 0.075% capsaicin applied three to four times a day greatly reduced pain (in week 2: 62% for capsaicin cream and 31% for placebo; in week 4: 77% for capsaicin and 31% for placebo) (Bernstein, 1989). In another study 0.075% capsaicin reduced pain by 28% at week 2 and 39% at week 6; of 83 patients followed for another 140 days, 86% of patients reported same or better pain relief with continued use (Watson, 1993).

    Several studies have looked at a lower concentration of capsaicin (0.025%) and found it also to be effective, although two or more weeks of treatment may be required to get the full benefit of the cream (Bernstein, 1987). A recent placebo-controlled study reported that there was an average decrease of approximately 15% of the magnitude of pain with topical 0.025% capsaicin cream (McCleane, 2000), PHN.

    Some people find it difficult to use capsaicin cream because of intense burning after initial applications. (Kanazi, 2000). However, this burning may lessen after repeated use of the cream.

  • Anticonvulsants: When nerve cells are damaged, they can become chronically overstimulated and continue to send pain messages to the brain even when there is no injury present.

    Anticonvulsant medications block the sodium channels along nerve membranes that cause nerve cells to activate, helping to quiet down these overactive nerves.

    The first-line drugs for neuropathic pains are two related anti-seizure medicines, gabapentin (Neurontin®) and pregabalin (Lyrica®), and a number of analgesic antidepressants. Gabapentin and pregabalin have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of specific neuropathic pains, including shingles. The most common side effects associated with these drugs are mental clouding and sleepiness.

    Numerous scientific studies, case reports and one large multicenter study have confirmed gabapentin's effectiveness in reducing pain as well as improving sleep, mood and quality of life. In addition gabapentin is generally well-tolerated, with a safety profile comparable to antidepressant treatment. Most frequent adverse effects include sleepiness, dizziness, unsteadiness, peripheral edema and infection. (Kanazi, 2000) (Rice, 2001) (Nicholson, 2000) (Rowbotham, 1998).

  • Antidepressants: Antidepressant drugs are nonspecific analgesics and the analgesic effects can occur independent of antidepressant actions (Robertson, 1990). The evidence is best for the so-called tricyclic antidepressants (Rowbotham, 2001) (Koltzenburg, 2001). Approximately half of patients with PHN benefit from therapy with a tricyclictricyclic antidepressant (Watson, 2000), such as amitriptyline (Elavil). In several small studies, amitriptyline provided significantly better pain relief than either placebo or other antidepressant medications (Watson, 1982, 1992) (Max, 1998). Nortriptyline (Aventil, Pamelor) has also has been found to have a significant analgesic effect and to have fewer adverse side effects (Kanazi, 2000) (Watson, 1998). Side effects of tricyclic antidepressants can include dry mouth, constipation, dizziness, nausea, diarrhea, insomnia, headache, blurred vision and drowsiness, among others. They should not be used by patients taking MAOI antidepressants, and should be used cautiously in the elderly, people with epilepsy, thyroid disease, liver disease, closed-angle glaucoma, and pregnant or breast-feeding women, among other conditions.

    There is also evidence that the newer antidepressants, such as venlafaxine (Effexor), bupropion (Wellbutrin), and paroxetine (Paxil) have analgesic properties. The overall effectiveness of these drugs is probably less than the tricyclic antidepressants, but the likelihood of troubling side effects is substantially less. Patients who are predisposed to tricyclic side effects, or who have not been able to tolerate these drugs, may be good candidates for trials of the newer antidepressants.

  • Opioid analgesics: Although opioid drugs are the most effective analgesics overall, some patients with neuropathic pain such as PHN do not respond well and many patients, particularly the elderly, struggle with side effects such as constipation and sleepiness. Many patients and physicians also fear these drugs because they are associated with the disease of addiction. Nonetheless, there is good evidence that PHN can be helped by opioids (Kanazi, 2000, Watson, 1998). The risks, including the risk of addiction are often overstated, particularly if the decision to try an opioid is made after a careful assessment that evaluates the severity and impact of the pain, the risk of side effects, the availability of other approaches, and the likelihood that the patient will be a responsible drug-taker.

  • Corticosteroids: Corticosteroid drugs such as prednisone and dexamethasone, may help with the pain and duration of shingles. They do not appear to reduce the likelihood of a patient developing PHN and are not used to treat the established pain syndrome. There have been recent positive studies that evaluated the spinal injection of a steroid for PHN (Kotani, 2000) (Kikuchi, 1999). These studies are provocative, but the technique has not been widely accepted because of concern about side effects and toxicity.

  • NSAIDS (non-steroidal anti-inflammatory drugs): NSAIDS have not been shown to be an effective treatment for PHN pain.

  • Other Drugs: Many other drugs are used to treat neuropathic pain and may be tried in cases of PHN. These include the oral local anesthetics (such as mexiletine), baclofen, and the so-called NMDA receptor antagonists (such as ketamine, dextromethorphan, amantadine, and memantine). A large body of experimental evidence in animal models of neuropathic pain suggests an important role of the activation of NMDA receptors. Studies using intravenous infusion of the NMDA receptor antagonist ketamine have shown a reduction in the magnitude of pain in humans with neuropathic pain, but a high incidence of side effects. (Eide, 1994) (Leung, 2001). Two small clinical trials tested the use of dextromethorphan (most commonly used as a cough suppressant medication) for painful diabetic peripheral neuropathy and PHN (Nelson, 1997). The results of these studies suggest that dextromethorphan may be effective for the treatment of painful diabetic peripheral neuropathy but there was no evidence of efficacy in PHN.

   

 

Home | Contact Us | Privacy Policy | Disclaimer | Site Map
This website is generously supported by Medtronic, Inc.
©2004 Continuum Health Partners, Inc.